Publication at Faculty of Medicine in Hradec Králové |
2019
Abstract
Every anticoagulation therapy is associated with an increased risk of bleeding. The risk of bleeding raises with the age and depends on the type and anticoagulation.
Therapy of bleeding depends on a severity of bleeding, indication of anticoagulation therapy and the comorbidities. In major and life-threatening bleeding we have at the disposal the antidotes protamine for unfractionated heparin and idarucizumab for dabigatran.
The effect of protamine is limited in low molecular weights heparin, in the case of xabans the concentrate of prothrombin complexes is therapy of choice. This concentrate and vitamin K are indicated in the bleeding associated with warfarin.